Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.11 CHF | -2.77% | -2.88% | -7.14% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
Sales 2023 * | 8.29M 9.1M | Sales 2024 * | 51.09M 56.09M | Capitalization | 83.95M 92.15M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 10.1 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.64 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 46 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.73% |
Latest transcript on Santhera Pharmaceuticals Holding AG
1 day | -2.77% | ||
1 week | -2.88% | ||
Current month | -6.76% | ||
1 month | -3.80% | ||
3 months | -8.53% | ||
6 months | -25.08% | ||
Current year | -7.14% |
Managers | Title | Age | Since |
---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 56 | 19-11-30 |
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Andrew P. Smith
DFI | Director of Finance/CFO | 61 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Director/Board Member | 56 | 17-04-03 | |
Otto Schwarz
BRD | Director/Board Member | 68 | 23-06-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 9.11 | -2.77% | 30,815 |
24-04-18 | 9.37 | -4.87% | 27,670 |
24-04-17 | 9.85 | +8.36% | 43,661 |
24-04-16 | 9.09 | -0.11% | 16,324 |
24-04-15 | 9.1 | -1.62% | 22,324 |
Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.14% | 94.75M | |
+10.08% | 9.12B | |
-17.63% | 4.8B | |
+0.73% | 3.8B | |
+16.55% | 3.72B | |
+27.76% | 2.58B | |
-26.11% | 2.36B | |
-30.09% | 2.11B | |
+7.15% | 1.86B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SANN Stock